Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

Maridebart cafraglutide, a novel injectable GIP receptor antagonist/GLP-1 receptor agonist, reduced body weight by ...

Madrigal Pharmaceuticals' strong launch is confirmed with impressive sales in Q1 and Q2. Learn why MDGL stock could benefit ...

New analysis from GlobalData spans the growth of the heart failure market across seven major markets including the US, Europe ...

Could tweaking your diet hold the key to eternal youth? The suggestion from recent research is that it can and even simple ...

The Elcella pill unlocks the body’s naturally occurring hormones in the colon, to send ‘fullness’ messages to the brain, ...

Diet food brands have been hit in recent years, but now GLP-1 drugs like Ozempic are hitting the market, will this spell the ...

Havas is forging deeper into the GLP-1 space with a series of YouTube videos about the drug class and its impact on the world ...

Digital technologies loom large on the list—from the growing impact of artificial intelligence to the need for tech-enabled ...

As employers grapple with including GLP-1s in their benefits packages, they face a complex decision that boils down to two ...

Holiday weight gain hits home for many come January. These days, folks making resolutions to slim down and get fit have an ...